Literature DB >> 10798369

A fragile X case with an amplification/deletion mosaic pattern.

D García Arocena1, Y de Diego, B A Oostra, R Willemsen, M Mirta Rodriguez.   

Abstract

Fragile X syndrome is the most common cause of hereditary mental retardation. The FMR1 gene, which is involved in fragile X syndrome, contains a polymorphic CGG repeat, which expands in affected patients. Expanding triplet repeats have been shown to be a new type of mutation, termed "dynamic mutation", responsible for more than 12 genetic diseases. These mutations occur as multiple steps rather than as a single event. The first step leads to an unstable allele that then becomes increasingly unstable generally achieving further increases in copy or occasionally contraction. In this report, we describe a fragile X boy with both a hypermethylated full mutation and a deletion of 905 bp encompassing the CGG repeat. The upstream breakpoint is 438 bp 5' to the CGG repeat and the downstream breakpoint is 420 bp 3' of the triplet repeats. The deletion includes the ATG starting codon for translation of the FMR1 gene. This was confirmed by using FMRP immunocytochemistry both on blood smears and hair roots. The deleted region is flanked by a ccgg direct repeat next to the breakpoints; this may have had a critical role in the formation of a secondary DNA structure leading to the deletion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10798369     DOI: 10.1007/s004390051052

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  9 in total

1.  Mutsβ generates both expansions and contractions in a mouse model of the Fragile X-associated disorders.

Authors:  Xiao-Nan Zhao; Daman Kumari; Shikha Gupta; Di Wu; Maya Evanitsky; Wei Yang; Karen Usdin
Journal:  Hum Mol Genet       Date:  2015-09-29       Impact factor: 6.150

Review 2.  Mutation spectra in fragile X syndrome induced by deletions of CGG*CCG repeats.

Authors:  Robert D Wells
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

3.  Small genomic rearrangements involving FMR1 support the importance of its gene dosage for normal neurocognitive function.

Authors:  Sandesh C S Nagamani; Ayelet Erez; Frank J Probst; Patricia Bader; Patricia Evans; Linda A Baker; Ping Fang; Terry Bertin; Patricia Hixson; Pawel Stankiewicz; David Nelson; Ankita Patel; Sau Wai Cheung
Journal:  Neurogenetics       Date:  2012-08-14       Impact factor: 2.660

Review 4.  On the wrong DNA track: Molecular mechanisms of repeat-mediated genome instability.

Authors:  Alexandra N Khristich; Sergei M Mirkin
Journal:  J Biol Chem       Date:  2020-02-14       Impact factor: 5.157

5.  Size and methylation mosaicism in males with Fragile X syndrome.

Authors:  Poonnada Jiraanont; Madhur Kumar; Hiu-Tung Tang; Glenda Espinal; Paul J Hagerman; Randi J Hagerman; Nuanchan Chutabhakdikul; Flora Tassone
Journal:  Expert Rev Mol Diagn       Date:  2017-11       Impact factor: 5.225

Review 6.  Recent advances in assays for the fragile X-related disorders.

Authors:  Bruce E Hayward; Daman Kumari; Karen Usdin
Journal:  Hum Genet       Date:  2017-09-02       Impact factor: 4.132

Review 7.  Mosaic FMR1 deletion causes fragile X syndrome and can lead to molecular misdiagnosis: a case report and review of the literature.

Authors:  Bradford Coffee; Morna Ikeda; Dejan B Budimirovic; Lawrence N Hjelm; Walter E Kaufmann; Stephen T Warren
Journal:  Am J Med Genet A       Date:  2008-05-15       Impact factor: 2.802

8.  Beyond Trinucleotide Repeat Expansion in Fragile X Syndrome: Rare Coding and Noncoding Variants in FMR1 and Associated Phenotypes.

Authors:  Cedrik Tekendo-Ngongang; Angela Grochowsky; Benjamin D Solomon; Sho T Yano
Journal:  Genes (Basel)       Date:  2021-10-22       Impact factor: 4.096

Review 9.  Repeat-mediated genetic and epigenetic changes at the FMR1 locus in the Fragile X-related disorders.

Authors:  Karen Usdin; Bruce E Hayward; Daman Kumari; Rachel A Lokanga; Nicholas Sciascia; Xiao-Nan Zhao
Journal:  Front Genet       Date:  2014-07-17       Impact factor: 4.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.